Preventive vaccines against bioterrorism: Evaluation of efficacy and safety

Vaccine

Volumn 23, Issue 1, 2004, Pages 84-90

  Horne, Amelia Dale ^a   Clifford, Julianne ^a   Goldenthal, Karen L ^a   Kleppinger, Cynthia ^a,b   Lachenbruch, Peter A ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Animal Rule; Immunogenicity; Non inferiority

Indexed keywords

ANTHRAX VACCINE; SMALLPOX VACCINE; VACCINE;

ANTHRAX; BIOLOGICAL WARFARE; CLINICAL PROTOCOL; CLINICAL TRIAL; CORRELATION ANALYSIS; CRYING; DATA ANALYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; EDEMA; FATALITY; FEVER; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNITY; IMMUNOGENICITY; NAUSEA; NONHUMAN; PAIN; PLAGUE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PROBABILITY; REVIEW; RISK ASSESSMENT; SEIZURE; SIDE EFFECT; SMALLPOX; STATISTICAL ANALYSIS; STATISTICAL MODEL; VACCINATION; VACCINE PRODUCTION;

EID: 7444243941     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.04.037     Document Type: Article

References (20)

1. D.A. Henderson The looming threat of bioterrorism Science 283 1999 1279 1282
2. K.L. Goldenthal, L.A. Falk, L. Ball, and A. Geber Prelicensure evaluation of combination vaccines Clin. Infect. Dis. 33 Suppl. 4 2001 S267 S273
3. A.D. Horne, P.A. Lachenbruch, P.R. Getson, and H.S. Hsu Analysis of studies to evaluate immune response to combination vaccines Clin. Infect. Dis. 33 Suppl. 4 2001 S306 S311
4. W.A. Orenstein, R.H. Bernier, and A.R. Hinman Assessing vaccine efficacy in the field Epidemiol. Rev. 10 1988 212 241
5. P.A. Lachenbruch Sensitivity, specificity, and vaccine efficacy Control. Clin. Trials 19 1998 569 574
6. M. Ewell Comparing methods for calculating confidence intervals for vaccine efficacy Stat. Med. 15 1996 2379 2392
7. A.D. Horne, P.A. Lachenbruch, and K.L. Goldenthal Intent-to-treat analysis and preventive vaccine efficacy Vaccine 19 2001 319 326
8. D.Y. Lin, T.R. Fleming, and V. De Gruttola Estimating the proportion of treatment effect explained by a surrogate marker Stat. Med. 16 1997 1515 1527
9. J. Sadoff, J.F. Heyse, P. Heaton, and M. Dallas Designing a study to evaluate whether the Merck rotavirus vaccine is associated with a rare adverse reaction (intussusception) Presentation in the conference on evaluation of new vaccines: how much safety data? Bethesda, MD 14-15 November 2000
10. International Conference on Harmonization Guideline on validation of analytical procedures Federal Register 60 40 1995 11260
11. T.L. Scofield Assay validation S. Chow Encyclopedia of biopharmaceutical statistics 2003 Marcel Dekker New York 63 71
12. R.T. Chen, S.C. Rastogi, and J.R. Mullen The Vaccine Adverse Event Reporting System (VAERS) Vaccine 12 1994 42 50
13. M.T. Niu, D.E. Erwin, and M.M. Braun Data mining in the US Vaccine Adverse Event Reporting System (VAERS): early detection of intussusception and other events after rotavirus vaccination Vaccine 19 2001 4627 4634
14. A.M. Friedlander, S.L. Welkos, and M.L.M. Pitt Postexposure prophylaxis against experimental inhalation anthrax J. Infect. Dis. 167 1993 1239 1242
15. Centers for Disease Control Update: investigation of bioterrorism-related anthrax - Connecticut, 2001 MMWR 50 2001 1077 1079
16. M. Meselson, J. Guillemin, and M. Hugh-Jones The Sverdlovsk anthrax outbreak of 1979 Science 266 1994 1202 1208
17. Food and Drug Administration New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible Federal Register 67 105 2002 37988 37998
18. S.R. Rosenthal, M. Merchlinsky, C. Kleppinger, and K.L. Goldenthal Developing new smallpox vaccines Emerg. Infect. Dis. 7 2001 920 926
19. J.G. Bremen, and D.A. Henderson Poxvirus dilemmas - monkeypox, smallpox, and biologic terrorism N. Engl. J. Med. 339 1998 556 559
20. S. Senn Testing for baseline balance in clinical trials Stat. Med. 13 1994 1715 1726